

Abstract Number: 3894 Poster Board Number: D0036 E-mail: pujol@oo.upc.edu

# **Objective horizontal heterophoria measurements using** a new vision analyzer

Jaume Pujol<sup>1</sup>, Rosa Borras<sup>1</sup>, Irene Claramunt<sup>1</sup>, Mireia Sanchez<sup>1</sup>, Alfonso Sanchez-Magan<sup>1</sup> Juan Carlos Ondategui-Parra<sup>1</sup>



<sup>1</sup>Davalor Research Center (DRC) – Universitat Politècnica de Catalunya, Terrassa, Spain.

Purpose: To compare the results of two subjective methods used to measure horizontal heterophoria with an objective method implemented in a prototype of a new vision analyzer (EVA) that records eye movements while the patient watches a true-3D videogame.

#### Introduction:

- Heterophoria is the relative deviation of the visual axes after breaking fusion.
- Nowadays, in clinical practice heterophoria can be measured using subjective methods (influenced by patient and examiner) or objective methods (influenced by examiner).
- An objective method based on the Alternating Cover Test has been implemented in a prototype (Figure 1) of a fully autonomous and automated vision analyzer (Eve and Vision Analyzer, EVA, DAVALOR, Spain), those eliminating examiner influence.



Figure 1: Prototype of Eye and Vision Analyser, EVA, used in this study

## Methods:

- Patients: 54 young healthy patients were selected for this study. The mean age  $\pm$  standard deviation (SD) was 21.5±1.5 years (range:19 to 24).
- Inclusion criteria: Far and Near Visual Acuity (VA) ≥ 0.0 logMAR; Spherical Ametropia ≤ ±6.00D; Astigmatism  $\leq$  3.00D; No previous history of amblyopia or strabismus, ocular pathology or history of eye surgery..

Modified Thorington (MT)

Stimulus dissociation: Maddox

3 measurements with a time

• The mean heterophoria value

patient

was

rod with horizontal orientation

Stimulus: Spotlight

interval of 5 sec.

considered.

each

(RE)

for

E≈50 lux

- Test distance: 40 cm
- Run time, including time for instructions, was also measured

Von Graefe with a line of letters (VGL)

- Stimulus dissociation: 15 PD BD (RE); 8PD BU (LE) using phoropter Risley prism.
- · Optotype: Vertical line of letters corresponding to a VA of 0,2 logMAR.
- Increment speed of prismatic diopters was 2PD/sec
- E≈450 lux
- 3 measurements with a time interval of 5 sec.
- The mean heterophoria value for each patient was considered.

**Objective Alternanting** Cover Test (OACT)

- While watching binocularly a 3-D video game, one of the patient eyes was occluded for 2 seconds. This procedure was repeated 5
- times alternating between each eve. Optotype: Letter corresponding to
- a VA of 0,2 logMAR
- Eye movements were recorded by the eye-tracker (30Hz).
- The mean heterophoria value for each patient was considered.

	Mean phoria±SD (PD)*	Run Time (sec)
VGL	$-6.7 \pm 6.0$	137 ± 20
МТ	-1.0 ± 3.8	83 ± 13
OACT	-2.0 ± 3.0	26 ± 5

	Mean difference (PD)	95% CI (PD)	ICC (%)
VGL vs MT	$-5.6 \pm 5.3$	4.8 to -16.0	61.2
VGL vs OACT	$-4.6 \pm 4.6$	9.0 to -13.6	61.9
MT vs OACT	0.9 ± 2.8	6.4 to -5.5	80.4

Mean phoria and run time for each method. \* Negative (positive) value exophoria (esophoria)





## Conclusions:

- The EVA prototype is a useful device to objectively measure horizontal heterophoria.
- Difference in heterophia values obtained using OACT and MT (considered the gold standard of subjective methods) is lower than 1PD (not clinically significant)
- OACT is over 3 times faster than MT and over 5 times faster than VGL.

## **References:**

- 1. Schroeder. T. (1996) Reliability of and Comparisons Among Methods of Measuring Dissociated Phoria, American Academy of Optometry, 73(6), 389-397.
- 2. Lam, AKC; Lam, A; Wong, K. (2005) Comparison of near heterophoria tests under varying conditions on an adult sample. Ophthalmic and Physiological Optics, 25(2): 162-167.
- 3. Sanker, N; Prabhu, A; Ray, A. (2002) A comparison of near-dissociated heterophoria test in free space. Clinical and experimental optometry, 95(6); 638-642.



Acknowledgements: This study was funded by the Spanish Ministry of Science and Innovation with the project grant DPI2011-30090-C02-01, the European Union and DAVALOR SALUD.

**Results:**